Article
Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients.
Pharmacogenomics - 1 Oct 2011
Chen Chia-Hui, Wang Sheng-Chang, Tsou Hsiao-Hui, Ho Ing-Kang, Tian Jia-Ni, Yu Cheng-Jou, Hsiao Chin-Fu, Chou Sun-Yuan, Lin Yen-Feng, Fang Kai-Chi, Huang Chieh-Liang, Su Lien-Wen, Fang Yong-Chun, Liu Ming-Lun, Lin Keh-Ming, Hsu Ya-Ting, Liu Shu Chih, Chen Andrew Ch, Liu Yu-Li
Abstract excerpt
AIM: Methadone maintenance therapy is one of the standard treatments for heroin addiction. The isozyme CYP3A4 of the CYP system is one of the metabolic enzymes, as well as CYP2B6, responsible for the metabolism of methadone. The aim of the present study is to evaluate the potential use of genetic polymorphisms in CYP3A4 as biomarkers for the prediction of methadone treatment responses. MATERIALS & METHODS: A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
